Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Biomet Biologics, a subsidiary of Zimmer Biomet, is a prominent developer of orthobiologics and regenerative medicine solutions. The company specializes in autologous therapies that harness a patient's own blood or bone marrow to treat musculoskeletal conditions, including platelet-rich plasma (PRP) and bone marrow aspirate concentrate (BMAC) systems. Their portfolio includes the nSTRIDE Autologous Protein Solution, designed to treat knee osteoarthritis by neutralizing inflammatory cytokines. Additionally, Biomet Biologics provides a range of bone graft substitutes and soft tissue repair products used in orthopedic and spinal surgeries. The company's technologies are focused on enhancing the body's natural healing response and improving clinical outcomes in sports medicine and trauma.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Biomet Biologics.